News

Register today for our Drug Discovery Today sponsored webinar on Drug Delivery as enabling tool for drug discovery and drug development. Ellis Meng of the University of Southern California will talk about the use of implantable devices for smart drug delivery and Eric Martel of CERB will talk about Refined rat pharmacology studies with infusion using implantable pumps. You can learn more or register by clicking here.
November 8, 2011
We will exhibit iPRECIOŽ at the Neuroscience 2011 Annual Meeting which is scheduled for Nov. 12-16 in Washington DC at the Walter E Washington Convention Center on booth 2718. Please drop by and learn about what is new. Pick up our latest technology report and register to get new product news.
October 9, 2011
iPRECIOŽ Technology Report has been published in Frontiers in Experimental Pharmacology and Drug Discovery an open-access publisher. The full report may be downloaded or read here.
Drug delivery: enabling technology for drug discovery and development.
Successful drug delivery using implantable pumps may be found in over 12,500 published articles. Their versatility in delivering continuous infusion, intermittent or complex infusion protocols acutely or chronically has made them ubiquitous in drug discovery and basic research.
July 29 , 2011
Bibliography Section updated
5 new references were added to bibliography section [http://www.iprecio.com/support/index.html]
April 26 , 2011
Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats.
This finding was reported by Shobo et al. where Olanzapine concentrations at all times were higher and more stable than in any other reports. [Science Direct Link]
March 2, 2011
Technical Note 8, “Defines the best practice intrathecal infusion administration using iPRECIOŽ pumps with customized intrathecal catheter part number 0220 from Recathco (http://www.recathco.com/).“
March 2, 2011
Data Sciences International (DSI) releases case study on iPRECIOŽ for 5-HT Administration. - This study demonstrated with an iPRECIOŽ pump that a smaller rate of 5-HT than previously employed elicits a hypotensive effect in S.D. rats. Case study can be downloaded from the link, http://www.datasci.com/pdf/information/CaseStudy_MSU-iPRECIO%205HT.pdf
January 27, 2011
Technical Note 7, “Materials Compatibility Kit for iPRECIOŽ Pump” is now available. Standard Operating Procedure (SOP) for evaluating the compatibility of vehicle/solvents and agents to iPRECIOŽ is described in detail.
January 26, 2011
We will exhibit iPRECIOŽ at the Experimental Biology 2011 which is scheduled for April 9 -13 2011, Walter E. Washington Convention Center in Washington, DC on booth 931.
December 16, 2010
We will exhibit iPRECIOŽ at the Neuroscience 2010 Annual Meeting which is scheduled for Nov. 13-17 in San Diego, CA at the San Diego Convention Center on booth 901.
September 9, 2010
See iPRECIOŽ at the Safety Pharmacology Society 10th Annual Meeting which is scheduled for Sept. 20-23 in Boston, MA on booth 204 and 205. (Data Sciences International)
August 31, 2010
Data Sciences International (DSI) releases case study on iPRECIOŽ for Ang II infusions where both AlzetŽ and iPRECIOŽ data are described. Case study can be downloaded from the link, http://www.datasci.com/pdf/information/CaseStudy_iPRECIO%20Comparison.pdf
July 22, 2010
Primetech will release Technical Note 6,
“Recommendations for Intracerebral Administration” at FENS 2010 (http://fens2010.neurosciences.asso.fr/), Amsterdam July 3rd to 7th 2010. Booth 342 Data Sciences International (DSI) and Booth 725 Linton Instruments ( Linton). 322OP: Starter Kit Cranial Infusion Kit for iPRECIOŽ Pump and 322OP/Kit: Cranial Infusion Kit for iPRECIOŽ pump are supplied by Plastics OneŽ (www.plastics1.com).
June 14, 2010
5-HT produces blood pressure lowering effect.
“The findings of this study are consistent with the initial hypothesis that 5-HT would produce a blood pressure lowering effect when the pump was turned on and blood pressure would return to normal when the pump was turned off. (0.2μl/hour) However, we did discover that instead of a dose response to 5-HT, we were able to achieve an equivalent effect at a much lower dose than had been previously studied.”
Robert Patrick Davis et al.; FASEB J. 2010 24:lb551
May 17, 2010